Significant dissociation of brain and plasma kinetics with antipsychotics

被引:128
作者
Tauscher, J
Jones, C
Remington, G
Zipursky, RB
Kapur, S
机构
[1] Univ Vienna, Dept Gen Psychiat, A-1050 Vienna, Austria
[2] Univ Toronto, Ctr Addict & Mental Hlth, Schizophrenia PET Program, Toronto, ON, Canada
[3] Univ Toronto, Ctr Addict & Mental Hlth, Schizophrenia & Continuing Care Program, Toronto, ON, Canada
[4] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
关键词
antipsychotics; pharmacokinetics; positron emission tomography; receptor occupancy; dopamine receptors; serotonin receptors; schizophrenia;
D O I
10.1038/sj.mp.4001009
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Current dosing regimens of psychotropic drugs are based on plasma kinetic considerations, although it is unclear whether plasma levels faithfully reflect brain kinetics of drugs.(1,2) To examine this, we compared the kinetics of plasma levels of two widely used antipsychotics, olanzapine and risperidone, vs the time course of their effects in the brain. We used positron emission tomography (PET) and [C-11]-labeled ligands to quantify striatal and extra-striatal dopamine-2 (D-2), and cortical serotonin-2A (5-HT2A) receptor occupancy in healthy subjects after a single dose, and in patients chronically treated for psychosis. We found a significant dissociation of brain and plasma kinetics. Mean plasma elimination half-lives of single doses of olanzapine and risperidone were 24.2 and 10.3 h, respectively, whereas it took on average 75.2 h with olanzapine, and 66.6 h with risperidone to decline to 50% of their peak striatal D-2 receptor occupancy. We found similar discrepancies between the time course of plasma levels and extra-striatal D-2 as well as 5-HT2A receptor occupancy. Our results question the current reliance on plasma kinetics as the main basis for dosing regimens of antipsychotics. Studies of brain kinetics may provide a sounder basis for determining dosing schedules of psychotropic medications.
引用
收藏
页码:317 / 321
页数:5
相关论文
共 25 条
[1]  
Aravagiri M, 1999, BIOPHARM DRUG DISPOS, V20, P369, DOI 10.1002/1099-081X(199911)20:8<369::AID-BDD200>3.0.CO
[2]  
2-6
[3]   STRIATAL DOPAMINE RECEPTOR OCCUPANCY DURING AND FOLLOWING WITHDRAWAL FROM NEUROLEPTIC TREATMENT - CORRELATIVE EVALUATION BY POSITRON EMISSION TOMOGRAPHY AND PLASMA PROLACTIN LEVELS [J].
BARON, JC ;
MARTINOT, JL ;
CAMBON, H ;
BOULENGER, JP ;
POIRIER, MF ;
CAILLARD, V ;
BLIN, J ;
HURET, JD ;
LOCH, C ;
MAZIERE, B .
PSYCHOPHARMACOLOGY, 1989, 99 (04) :463-472
[4]  
Berna M, 1998, J MASS SPECTROM, V33, P1003, DOI 10.1002/(SICI)1096-9888(1998100)33:10<1003::AID-JMS716>3.0.CO
[5]  
2-P
[6]  
BORISON RL, 1994, PSYCHOPHARMACOL BULL, V30, P193
[7]   Olanzapine - Pharmacokinetic and pharmacodynamic profile [J].
Callaghan, JT ;
Bergstrom, RF ;
Ptak, LR ;
Beasley, CM .
CLINICAL PHARMACOKINETICS, 1999, 37 (03) :177-193
[8]  
FARDE L, 1988, ARCH GEN PSYCHIAT, V45, P71
[9]   A PET study of [C-11]FLB 457 binding to extrastriatal D-2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients [J].
Farde, L ;
Suhara, T ;
Nyberg, S ;
Karlsson, P ;
Nakashima, Y ;
Hietala, J ;
Halldin, C .
PSYCHOPHARMACOLOGY, 1997, 133 (04) :396-404
[10]  
Gifford AN, 1998, SYNAPSE, V28, P167, DOI 10.1002/(SICI)1098-2396(199802)28:2<167::AID-SYN7>3.0.CO